Tyrosine Kinase Inhibitor
- CAS No.
- 649735-46-6
- Chemical Name:
- Tyrosine Kinase Inhibitor
- Synonyms
- CS-75;Brivanib;Bms540215;Bms 540215;Unii-ddu33B674i;Brivanib, >=98%;Brivanib(BMS-540215);BMS540215; BMS 540215;Tyrosine Kinase Inhibitor;Brivanib/Tyrosine Kinase Inhibitor
- CBNumber:
- CB00131632
- Molecular Formula:
- C19H19FN4O3
- Molecular Weight:
- 370.38
- MDL Number:
- MFCD13194684
- MOL File:
- 649735-46-6.mol
- MSDS File:
- SDS
| Density | 1.42 |
|---|---|
| storage temp. | Store at -20°C |
| solubility | insoluble in H2O; ≥18.5 mg/mL in DMSO; ≥3.39 mg/mL in EtOH with ultrasonic |
| form | Yellow powder. |
| pka | 14.18±0.20(Predicted) |
| color | White to light brown |
| NCI Dictionary of Cancer Terms | tyrosine kinase inhibitor |
| FDA UNII | DDU33B674I |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS08 |
|---|---|
| Signal word | Danger |
| Hazard statements | H360-H373-H361 |
| Precautionary statements | P260-P314-P501-P201-P202-P281-P308+P313-P405-P501 |
Tyrosine Kinase Inhibitor price More Price(35)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich | SML3671 | Brivanib ≥98% (HPLC) | 649735-46-6 | 5MG | $119 | 2024-03-01 | Buy |
| Sigma-Aldrich | SML3671 | Brivanib ≥98% (HPLC) | 649735-46-6 | 25MG | $479 | 2024-03-01 | Buy |
| Cayman Chemical | 23690 | Brivanib ≥95% | 649735-46-6 | 1mg | $32 | 2024-03-01 | Buy |
| Cayman Chemical | 23690 | Brivanib ≥95% | 649735-46-6 | 5mg | $131 | 2024-03-01 | Buy |
| Cayman Chemical | 23690 | Brivanib ≥95% | 649735-46-6 | 10mg | $214 | 2024-03-01 | Buy |
Tyrosine Kinase Inhibitor Chemical Properties,Uses,Production
Uses
Brivanib is an ATP-competitive inhibitor against human VEGFR2 and FGFR with IC50 of 25 nM and 148 nM, respectively.
Definition
ChEBI: Brivanib is a secondary alcohol resulting from the hydrolysis of the carboxylic ester group of brivanib alaninate. It is a dual VEGFR-2/FGFR-1 kinase inhibitor whose alanine prodrug, brivanib alaninate is currently under development as an oral agent for the treatment of cancer. It has a role as an antineoplastic agent, an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor, an angiogenesis inhibitor, an apoptosis inducer, a fibroblast growth factor receptor antagonist and a drug metabolite. It is a pyrrolotriazine, a fluoroindole, a diether, an aromatic ether and a secondary alcohol.
Biological Activity
brivanib is an atp competitive inhibitor of human vegfr-2 with ic50 value of 25nm [1].brivanib is a selective rtk inhibitor that targets signaling via vegfr2 and 3, and fgfr1, 2 and 3. targeting both vegf and fgf signaling pathways inhibits tumor growth in rt2 mice, with vegf signaling predominating in initiation of tumor angiogenesis, currently, brivanib therapy is being evaluated in phase iii
target
VEGFR-2
References
[1] rajeev s. bhide, zhen-wei cai, yong-zheng zhang, ligang qian, donna wei, stephanie barbosa, louis j. lombardo, robert m. borzilleri, xiaoping zheng, laurence i. wu, joel c. barrish, soong-hoon kim, kenneth leavitt, arvind mathur, leslie leith, sam chao, barri wautlet, steven mortillo, robert jeyaseelan sr., daniel kukral, john t. hunt, amrita kamath, aberra fura, viral vyas, punit marathe, celia d’arienzo, george derbin, and joseph fargnoli. discovery and preclinical studies of (r)-1-(4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol (bms-540215), an in vivo active potent vegfr-2 inhibitor. journal of medicinal chemistry. 2006, 49 (7): 2143-2146.
[2] elizabeth allen, ian b. walters, and douglas hanahan. brivanib, a dual fgf/vegf inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to vegf inhibition. clinical cancer research. 2011 (17): 5299-5310.
Tyrosine Kinase Inhibitor Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Jinan Carbotang Biotech Co.,Ltd. | +8615866703830 | figo.gao@foxmail.com | China | 8497 | 58 |
| Hubei Jusheng Technology Co.,Ltd. | 18871490254 | linda@hubeijusheng.com | CHINA | 28172 | 58 |
| BOC Sciences | +1-631-485-4226 | inquiry@bocsci.com | United States | 19553 | 58 |
| Alchem Pharmtech,Inc. | 8485655694 | sales@alchempharmtech.com | United States | 63687 | 58 |
| CONIER CHEM AND PHARMA LIMITED | +8618523575427 | sales@conier.com | China | 49374 | 58 |
| career henan chemical co | +86-0371-86658258 +8613203830695 | factory@coreychem.com | China | 29811 | 58 |
| Dideu Industries Group Limited | +86-29-89586680 +86-15129568250 | 1026@dideu.com | China | 22883 | 58 |
| Zhejiang J&C Biological Technology Co.,Limited | +1-2135480471 +1-2135480471 | sales@sarms4muscle.com | China | 10473 | 58 |
| InvivoChem | +1-708-310-1919 +1-13798911105 | sales@invivochem.cn | United States | 6391 | 58 |
| Hefei TNJ Chemical Industry Co.,Ltd. | +86-0551-65418684 +8618949823763 | sales@tnjchem.com | China | 25356 | 58 |
View Lastest Price from Tyrosine Kinase Inhibitor manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2024-11-19 | Tyrosine kinase-IN-7
345615-74-9
|
US $40.00-30.00 / mg | 99.93% | 10g | TargetMol Chemicals Inc. | ||
 |
2024-11-11 | PDGFR Tyrosine Kinase Inhibitor III
205254-94-0
|
US $30.00-118.00 / mg | 99.64% | 10g | TargetMol Chemicals Inc. | ||
 |
2019-12-23 | Btk Kinase inhibitor
1351636-18-4
|
US $1.00 / KG | 1KG | 99% | 100KG | Career Henan Chemical Co |
-
- Tyrosine kinase-IN-7
345615-74-9
- US $40.00-30.00 / mg
- 99.93%
- TargetMol Chemicals Inc.
-
- PDGFR Tyrosine Kinase Inhibitor III
205254-94-0
- US $30.00-118.00 / mg
- 99.64%
- TargetMol Chemicals Inc.
-
- Btk Kinase inhibitor
1351636-18-4
- US $1.00 / KG
- 99%
- Career Henan Chemical Co